223 related articles for article (PubMed ID: 31076406)
1. Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia.
Izaguirre-Carbonell J; Christiansen L; Burns R; Schmitz J; Li C; Mokry RL; Bluemn T; Zheng Y; Shen J; Carlson KS; Rao S; Wang D; Zhu N
Blood Adv; 2019 May; 3(9):1499-1511. PubMed ID: 31076406
[TBL] [Abstract][Full Text] [Related]
2. JMJD1C-regulated lipid synthesis contributes to the maintenance of
Qi D; Wang J; Zhao Y; Yang Y; Wang Y; Wang H; Wang L; Wang Z; Xu X; Hu Z
Leuk Lymphoma; 2022 Sep; 63(9):2149-2160. PubMed ID: 35468015
[No Abstract] [Full Text] [Related]
3. Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells.
Xu X; Wang L; Hu L; Dirks WG; Zhao Y; Wei Z; Chen D; Li Z; Wang Z; Han Y; Wei L; Drexler HG; Hu Z
Int J Cancer; 2020 Jan; 146(2):400-412. PubMed ID: 31271662
[TBL] [Abstract][Full Text] [Related]
4. shRNA screening identifies JMJD1C as being required for leukemia maintenance.
Sroczynska P; Cruickshank VA; Bukowski JP; Miyagi S; Bagger FO; Walfridsson J; Schuster MB; Porse B; Helin K
Blood; 2014 Mar; 123(12):1870-82. PubMed ID: 24501218
[TBL] [Abstract][Full Text] [Related]
5. JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.
Lynch JR; Salik B; Connerty P; Vick B; Leung H; Pijning A; Jeremias I; Spiekermann K; Trahair T; Liu T; Haber M; Norris MD; Woo AJ; Hogg P; Wang J; Wang JY
Leukemia; 2019 Jun; 33(6):1400-1410. PubMed ID: 30622285
[TBL] [Abstract][Full Text] [Related]
6. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.
Chen M; Zhu N; Liu X; Laurent B; Tang Z; Eng R; Shi Y; Armstrong SA; Roeder RG
Genes Dev; 2015 Oct; 29(20):2123-39. PubMed ID: 26494788
[TBL] [Abstract][Full Text] [Related]
7. The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential.
Wong SH; Goode DL; Iwasaki M; Wei MC; Kuo HP; Zhu L; Schneidawind D; Duque-Afonso J; Weng Z; Cleary ML
Cancer Cell; 2015 Aug; 28(2):198-209. PubMed ID: 26190263
[TBL] [Abstract][Full Text] [Related]
8. Modulators of histone demethylase JMJD1C selectively target leukemic stem cells.
Yang Y; Zhang X; Zhang X; Wang Y; Wang X; Hu L; Zhao Y; Wang H; Wang Z; Wang H; Wang L; Dirks WG; Drexler HG; Xu X; Hu Z
FEBS Open Bio; 2021 Jan; 11(1):265-277. PubMed ID: 33289299
[TBL] [Abstract][Full Text] [Related]
9. CRISPR Gene Editing of Murine Blood Stem and Progenitor Cells Induces MLL-AF9 Chromosomal Translocation and MLL-AF9 Leukaemogenesis.
Sarrou E; Richmond L; Carmody RJ; Gibson B; Keeshan K
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32549410
[TBL] [Abstract][Full Text] [Related]
10. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
[TBL] [Abstract][Full Text] [Related]
11. MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C.
Zhu N; Chen M; Eng R; DeJong J; Sinha AU; Rahnamay NF; Koche R; Al-Shahrour F; Minehart JC; Chen CW; Deshpande AJ; Xu H; Chu SH; Ebert BL; Roeder RG; Armstrong SA
J Clin Invest; 2016 Mar; 126(3):997-1011. PubMed ID: 26878175
[TBL] [Abstract][Full Text] [Related]
12. Comparative integromics on JMJD1C gene encoding histone demethylase: conserved POU5F1 binding site elucidating mechanism of JMJD1C expression in undifferentiated ES cells and diffuse-type gastric cancer.
Katoh M; Katoh M
Int J Oncol; 2007 Jul; 31(1):219-23. PubMed ID: 17549425
[TBL] [Abstract][Full Text] [Related]
13.
Fu JF; Shih LY; Yen TH
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34080665
[TBL] [Abstract][Full Text] [Related]
14. AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase.
Yoshihama Y; LaBella KA; Kim E; Bertolet L; Colic M; Li J; Shang X; Wu CJ; Spring DJ; Wang YA; Hart T; DePinho RA
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34475205
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
16. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
17. Bioinformatic Analyses of Broad H3K79me2 Domains in Different Leukemia Cell Line Data Sets.
Sharma P; Sattarifard H; Fatemiyan N; Lakowski TM; Davie JR
Cells; 2022 Sep; 11(18):. PubMed ID: 36139405
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
19. Jmjd1c demethylates STAT3 to restrain plasma cell differentiation and rheumatoid arthritis.
Yin Y; Yang X; Wu S; Ding X; Zhu H; Long X; Wang Y; Zhai S; Chen Y; Che N; Chen J; Wang X
Nat Immunol; 2022 Sep; 23(9):1342-1354. PubMed ID: 35995859
[TBL] [Abstract][Full Text] [Related]
20. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
